Johnson & Johnson $JNJ Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 432,376 shares of the company’s stock after buying an additional 38,570 shares during the period. Johnson & Johnson accounts for 0.3% of Rakuten Investment Management Inc.’s investment portfolio, making the stock its 28th largest position. Rakuten Investment Management Inc.’s holdings in Johnson & Johnson were worth $115,691,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Wellington Management Group LLP boosted its position in Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the period. Deutsche Bank AG increased its stake in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi raised its position in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the period. Jupiter Topco LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $1,967,399,000. Finally, Janus Henderson Group PLC boosted its holdings in Johnson & Johnson by 1.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $276.62 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02. The stock has a market cap of $665.92 billion, a PE ratio of 41.91, a P/E/G ratio of 2.63 and a beta of 0.22. The firm has a 50 day simple moving average of $265.67 and a two-hundred day simple moving average of $247.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. HSBC boosted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Bank of America reaffirmed a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Finally, Leerink Partners reduced their price target on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.